Overview

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Karelizumab Combined With Etoposide and Cisplatin

Status:
Not yet recruiting

Trial end date:
2026-08-31

Target enrollment:

Participant gender:

Summary

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Etoposide